Apotex has set up state-of-the art R&D and Manufacturing facilities in India for both Active Pharmaceutical Ingredients (API's) and Solid Dose Formulations. These facilities are located at the Bommasandra Industrial Area located in outskirts of the city of Bangalore.
The R&D activities will initially focus on developing solid dose formulations which will increase our capacity to deliver a greater number of new product submissions to our three key markets, Canada, US and Europe. Upon regulatory approval these products will be either manufactured in India or Canada. The R&D team will also provide Technical Support to Toronto for method development, validation and stability studies.
In addition a Bioequivalance Centre in support of the ever-increasing number of biostudies that are required to meet the regulatory requirements of our new products has also been established.
Apotex India Structure
- Apotex Research Private Ltd. (ARPL)
- Apotex Pharmachem Inc. Private Ltd. (APIPL)